Sana Biotechnology, Inc. Common Stock
SANASana Biotechnology, Inc. focuses on developing regenerative medicine and gene therapy solutions. The company aims to create and deliver engineered cells as medicines for various diseases, utilizing advancements in cell engineering and gene editing technologies to treat conditions with unmet medical needs.
Company News
Kailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showin...
U.S. stock futures rose on Tuesday following Monday's rally, with major indices trading higher. Vice President JD Vance signaled potential progress in Iran nuclear talks if Tehran meets U.S. demands. Investors await March producer price index data. Key movers include Sana Biotechnology surging 20% on Mayo Clinic collaboration, ChargePoint jumping...
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.
Quell Therapeutics has formed a Scientific Advisory Board comprising leading experts in immunology, T-regulatory cell biology, and autoimmune diseases to guide its innovative CAR-Treg cell therapy development.
